Split History
ETFs Holding TGTX »    TGTX Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
TG Therapeutics is a biopharmaceutical company focuses on developing and delivering medicines for patients with B-cell mediated diseases, including Chronic Lymphocytic Leukemia (CLL), non-Hodgkin's Lymphoma (NHL) and Multiple Sclerosis (MS). Co. has developed a B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Co. has five B-cell targeted drug candidates in clinical development, with the two therapies, ublituximab (TG-1101) and umbralisib (TGR-1202), in pivotal trials for CLL, NHL and MS. Ublituximab is an anti-CD20 monoclonal antibody. Umbralisib is an oral, once daily inhibitor of PI3K delta. According to our TGTX split history records, TG Therapeutics has had 2 splits.
TGTX split history picture
TG Therapeutics (TGTX) has 2 splits in our TGTX split history database. The first split for TGTX took place on July 14, 2011. This was a 1 for 50 reverse split, meaning for each 50 shares of TGTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split. TGTX's second split took place on July 19, 2011.

When a company such as TG Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the TGTX split history from start to finish, an original position size of 1000 shares would have turned into 20 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TG Therapeutics shares, starting with a $10,000 purchase of TGTX, presented on a split-history-adjusted basis factoring in the complete TGTX split history. TGTX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/03/2010
End date: 10/18/2019
Start price/share: $4.00
End price/share: $5.46
Dividends collected/share: $0.00
Total return: 36.50%
Average Annual Total Return: 3.34%
Starting investment: $10,000.00
Ending investment: $13,647.77
Years: 9.47
Date Ratio
07/14/20111 for 50
07/19/20111 for 1
TGTX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

TGX Split History
THC Split History
THRX Split History
TLB Split History
TMO Split History
TNDM Split History
TNXP Split History
TOS Split History
TPIV Split History
TRL Split History

Also explore: TGTX shares outstanding history

Aethlon Medical, Inc. (AEMD)
Aberdeen Standard Physical Gold Shares ETF (SGOL)
Safe-T Group Ltd. (SFET)
NanoViricides, Inc. (NNVC)
Penns Woods Bancorp, Inc. (PWOD)
MoSys, Inc. (MOSY)
TOP Ships Inc. (TOPS)
Interlapse Technologies Corp. (INLA.CA)
SINTX Technologies, Inc. (SINT)
Pluristem Therapeutics Inc. (PSTI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

TGTX Insider Buying

TGTX Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.